CK-3773274 (10 - 30 mg) for Hypertrophic Cardiomyopathy (REDWOOD-HCM Trial)

"The safety of CK-3773274 (10 - 30 mg) was assessed to be a 2 on the 1 to 3 scale, as this is an ongoing Phase 2 trial. Despite some evidence regarding its security there has yet been no proof of efficacy found thus far."

"This clinical trial is being held at 18 distinct medical centres, including Intermountain Medical Center in Murray, the Oregon Health and Science University in Portland and Tufts Medical Center in Boston."

"This clinical trial seeks to recruit 95 patients, aged 18-85, who suffer from obstructive hypertrophic cardiomyopathy. To be eligible for the study, individuals must weigh at least 45kg and have adequate acoustic windows for echocardiography; a resting gradient of ≥50mmHg or ≥30 mmHg with post-Valsalva LVOT-G≥50 mmHg (for Cohort 4 has resting and post-Valsalva LVOT below 30mmHg); an LVEF score of 60% or above; minimal wall thickness between 13 and 15mm (13 is"

"Cytokinetics, the clinical trial sponsor has reported that this study's primary endpoint is to measure adverse events experienced by patients with HCM over a 14-week period. Alongside this, secondary objectives will evaluate the concentration-response relationship of CK-3773274 on post-Valsalva left ventricular outflow tract gradient (LVOT-G), dose response relationship of CK-3773274 in resting oHCM, and patient incidence of left ventricular ejection fraction (LVEF) < 50% during dosing."

"Per the records found on clinicaltrials.gov, patient recruitment for this specific medical trial has ceased; it was initially posted in October 1st 2020 and last updated November 3rd 2022. Nonetheless, there are a plethora of other trials actively seeking participants at present."

"This trial invites individuals aged 18 to 85, with a total of 25 trials focused on minors and 194 studies catering to those more than 65 years old."